Antimicrobial, Antiviral & Terrain Support

Cancer does not happen in isolation.

It happens in a body with a microbiome, an immune system, a gut barrier, and continuous microbial exposure.

That terrain matters even more during chemotherapy, immunotherapy, antibiotic exposure, steroid use, and treatment-related immune suppression.

For Urolithin A, the terrain evidence is now stronger than this page previously reflected.

It includes published data across:

• antibacterial activity

• antiviral inflammation control

• antiparasitic activity

• early antifungal activity

• gut-barrier support

• microbiome remodelling

• human innate-immune phagocytosis data

• skeletal muscle and mitochondrial support

This page does not claim that Urolithin A replaces antibiotics, antifungals, antivirals, or antiparasitic drugs.

It asks a different question.

Does Urolithin A support the biological terrain that cancer treatment depends on?

In several areas, the answer now looks like yes.

Why this matters

Terrain biology is not a side issue in oncology.

Gut-barrier failure, dysbiosis, opportunistic infection, inflammatory overreaction, and impaired innate immunity all change treatment tolerance and recovery.

That is why this page belongs here even when some findings do not have a direct tumour-cell anchor.

Antibacterial activity

Broad-spectrum in vitro coverage

Urolithin A has shown antibacterial activity against both Gram-positive and Gram-negative organisms.

Published in vitro data includes activity against:

• Escherichia coli

• Staphylococcus aureus

• Bacillus subtilis, Bacillus cereus, and Bacillus polymyxa

• Vibrio cholerae

• Shigella dysenteriae

• Campylobacter species

The reported mechanisms are broader than simple growth inhibition.

They include reduced biofilm biomass and disruption of quorum sensing.

That matters.

Quorum sensing helps bacteria coordinate virulence, biofilm formation, and resistance-related behaviour.

MRSA and carbapenem-resistant Acinetobacter baumannii

This is one of the more clinically relevant terrain findings.

Urolithin A has shown inhibitory activity against:

• MRSA

• carbapenem-resistant Acinetobacter baumannii

The reported mechanism was quorum-sensing disruption rather than classic antibiotic killing.

That is important because quorum-sensing inhibition may reduce pathogenicity without applying the same direct resistance pressure as conventional antibiotics.

For immunocompromised cancer patients, that is a meaningful distinction.

Human relevance — better bacterial phagocytosis

The most important human finding comes from the 2025 Nature Aging trial.

After four weeks of Urolithin A supplementation, monocytes from supplemented participants showed stronger ex vivo phagocytosis of E. coli particles than monocytes from the placebo group.

That is the first direct human evidence that oral Urolithin A can improve a bacteria-clearing innate-immune function.

This was not a cancer-patient cohort.

Even so, it makes the terrain argument much stronger.

It shows the immune effect is not just theoretical.

Antiviral activity

Urolithin A is not a direct antiviral in the usual sense.

It does not appear to kill viruses directly.

What it does is modulate the host inflammatory response to viral-pattern signalling.

TLR3 and TRIF signalling

TLR3 detects double-stranded RNA.

That is one of the main immune signatures of viral replication.

TLR3 activation can drive NF-κB and MAPK signalling and amplify inflammatory cytokine output.

Urolithin A has been shown to suppress TLR3/TRIF signalling in macrophages stimulated with poly(I:C), a viral RNA mimic.

That reduced downstream inflammatory signalling.

The implication is not viral clearance.

It is control of viral-overreaction biology.

That can matter in severe respiratory infections and in patients already dealing with treatment-related inflammatory burden.

COVID-19 context

A 2023 review discussed Urolithin A as a theoretical adjunct in COVID-19 because of its effects on TLR3/TRIF, NF-κB, and AhR-linked inflammatory biology.

That remains speculative.

No clinical study has tested Urolithin A in COVID-19 treatment.

Still, it is a useful example of how the antiviral relevance works.

The interest is in hyperinflammation control, not antiviral drug replacement.

Antiparasitic activity — Toxoplasma gondii

This is one of the most unexpected findings in the Urolithin A literature.

Toxoplasma gondii can remain dormant in tissue cysts for years.

In immunocompromised patients, reactivation can become clinically serious.

That makes this terrain finding more relevant than it first sounds.

Published work showed that Urolithin A:

• reduced tachyzoite burden in infected human neural cells

• interfered with cyst development

• led to smaller brain cysts in chronically infected mice

• altered predator-cue behaviour in infected mice in a direction consistent with lower neural parasite burden

This is not routine clinical evidence.

It is still striking.

It suggests Urolithin A can influence a persistent intracellular parasite in both cell and animal systems.

For cancer patients at risk of immunosuppression-related reactivation, that is worth tracking.

Antifungal activity

The antifungal evidence is earlier than the antibacterial evidence.

It still exists.

Published in vitro work reports inhibitory activity against:

• Candida species

• Aspergillus niger

The signal appears weaker than the antibacterial signal.

Even so, it is relevant in oncology because fungal overgrowth and opportunistic fungal infection become more common during chemotherapy, antibiotic exposure, and steroid use.

One related study on a Urolithin-A-producing E. faecium strain also showed antimicrobial inhibition zones against both Candida and A. niger.

That does not prove oral Urolithin A treats fungal infection.

It does support the broader terrain relevance.

Gut-barrier integrity

This may be the most important terrain section on the page.

The gut barrier helps determine microbial translocation, systemic inflammation, and immune balance.

In cancer care, it is easily disrupted.

Chemotherapy, antibiotics, stress, and poor intake can all weaken it.

Urolithin A has shown several barrier-supportive actions:

• activation of AhR and Nrf2 signalling in intestinal cells

• reduced gut permeability in colitis models

• improved tight-junction protein expression

• modulation of tryptophan metabolism toward indole-3-aldehyde production

• support of the AhR/IL-22 axis that helps epithelial repair

This links closely with the wider immune biology covered on the Immune Effects page.

The same signalling nodes that matter for immune tone also matter for mucosal defence.

Skeletal muscle biology — an emerging terrain dimension

Muscle loss is not a side effect that happens after cancer treatment ends.

It begins during treatment and accelerates with every week of reduced activity, inflammatory burden, poor nutrient absorption, and gut-barrier disruption.

That makes muscle biology a terrain issue, not just a rehabilitation issue.

Cancer-related sarcopenia affects an estimated 40–70% of oncology patients depending on tumour type.

It is independently associated with poorer treatment tolerance, increased chemotherapy toxicity, reduced quality of life, and shorter survival.

As systemic therapies improve and patients live longer on active treatment, preserving skeletal muscle mass has become one of the most clinically meaningful — and underserved — areas of supportive oncology care.

How Urolithin A fits here

Urolithin A works on muscle biology through a distinct mechanism from most compounds discussed in this field.

Its primary action is mitophagy induction — the cellular process of clearing damaged, dysfunctional mitochondria and replacing them with new ones.

In skeletal muscle, mitochondrial quality determines endurance capacity, energy production, and resistance to atrophy.

When mitochondria accumulate damage — as they do during chemotherapy, inflammation, and inactivity — muscle function declines even when muscle mass appears preserved.

Urolithin A reverses this at the cellular level.

What the human trials show

A 2022 randomised controlled trial in Cell Reports Medicine found that 1000 mg/day of Urolithin A for four months in adults aged 65–90 significantly improved skeletal muscle endurance in both leg and hand grip testing compared to placebo.

Mitochondrial health biomarkers improved.

Critically, these benefits were observed without structured exercise training.

That is clinically significant for cancer patients who cannot exercise due to fatigue, nausea, or treatment side effects.

A 2022 JAMA Network Open trial confirmed long-term Urolithin A supplementation enhanced skeletal muscle–specific endurance, with a good safety profile.

Microbiome remodelling

Urolithin A does not just affect barrier proteins.

It also shifts microbiome composition.

That matters because terrain failure is often ecological, not just cellular.

Reported findings include:

• increased Akkermansia muciniphila which is strongly linked to mucus-layer integrity and better barrier function.

• reduced Desulfovibrio which is often linked to barrier disruption and pro-inflammatory signalling.

• improved dysbiosis patterns in colitis and related animal models

Evidence level summary

References

Urolithins and their antimicrobial activity: a short review
https://dergipark.org.tr/en/download/article-file/1245343

Effect of the mitophagy inducer Urolithin A on age-related immune decline
https://www.nature.com/articles/s43587-025-00996-x

Urolithin A inactivation of TLR3/TRIF signalling to block NF-κB and MAPK
https://pubmed.ncbi.nlm.nih.gov/35563088/

Urolithin A attenuates neurotoxoplasmosis and alters innate immunity in Toxoplasma gondii infection
https://pmc.ncbi.nlm.nih.gov/articles/PMC8474456/

In vitro and computational analysis of Urolithin A for anti-infective properties
https://www.sciencedirect.com/science/article/pii/S1319562X23002498

Unveiling the potential of Urolithin A in cancer therapy — mechanistic insights to future perspectives
https://pmc.ncbi.nlm.nih.gov/articles/PMC12188533/

Urolithin A alleviates colitis in mice by improving gut microbiota dysbiosis, modulating tryptophan metabolism and AhR/IL-22 axis
https://pubs.acs.org/doi/10.1021/acs.jafc.3c00830

Genetic and probiotic characteristics of Urolithin-A-producing E. faecium FUA027
https://pmc.ncbi.nlm.nih.gov/articles/PMC10001356/

Can Urolithin A help in curing COVID-19 infection?
https://www.qeios.com/read/BXMNT4

Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults
https://www.sciencedirect.com/science/article/pii/S2666379122001586

Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2788244

Lemon Myrtle (Backhousia citriodora) Extract and Its Active Compound, Casuarinin, Activate Skeletal Muscle Satellite Cells In Vitro and In Vivo
https://pubmed.ncbi.nlm.nih.gov/35268053/